Recent Analysts’ Ratings Updates for Incyte (INCY)

A number of firms have modified their ratings and price targets on shares of Incyte (NASDAQ: INCY) recently:

• 11/5/2026 – Incyte had its price target lowered by Leerink Partners from $154.00 to $150.00. They now have an “outperform” rating on the stock.
• 11/4/2026 – Incyte was downgraded by Weiss Ratings from “buy (b)” to “hold (c)”.
• 11/2/2026 – Incyte had its price target raised by Sanford C. Bernstein from $104.00 to $108.00. They now have a “market perform” rating on the stock.
• 10/30/2026 – Incyte was given a new $152.00 price target by UBS Group.
• 10/30/2026 – Incyte had its price target lowered by Wells Fargo & Company from $128.00 to $127.00. They now have an “equal weight” rating on the stock.
• 10/30/2026 – Incyte had its price target raised by Royal Bank Of Canada from $114.00 to $117.00. They now have a “sector perform” rating on the stock.
• 10/30/2026 – Incyte had its price target raised by Barclays from $139.00 to $143.00. They now have an “overweight” rating on the stock.
• 10/27/2026 – Incyte had its “market perform” rating reaffirmed by BMO Capital Markets.
• 10/27/2026 – Incyte was given a new $152.00 price target by Oppenheimer.
• 10/27/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright.
• 10/23/2026 – Incyte was downgraded by Weiss Ratings from “buy (b+)” to “buy (b)”.
• 10/21/2026 – Incyte had its price target raised by TD Cowen from $138.00 to $140.00. They now have a “buy” rating on the stock.
• 10/20/2026 – Incyte is now covered by Morgan Stanley. They set an “equal weight” rating and a $119.00 price target on the stock.
• 10/16/2026 – Incyte was given a new $152.00 price target by Raymond James Financial.
• 10/14/2026 – Incyte had its price target raised by Truist Financial from $105.00 to $115.00. They now have a “hold” rating on the stock.
• 10/14/2026 – Incyte was downgraded by Zacks Research from “hold” to “strong sell”.
• 10/13/2026 – Incyte had its “buy” rating reaffirmed by Benchmark.
• 10/13/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $152.00 price target on the stock.
• 10/10/2026 – Incyte was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/8/2026 – Incyte was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 10/8/2026 – Incyte had its price target raised by Royal Bank Of Canada from $109.00 to $114.00. They now have a “sector perform” rating on the stock.
• 10/5/2026 – Incyte had its “neutral” rating reaffirmed by UBS Group. They now have a $127.00 price target on the stock.
• 10/5/2026 – Incyte had its price target raised by Stifel Nicolaus from $145.00 to $157.00. They now have a “buy” rating on the stock.
• 10/1/2026 – Incyte had its price target raised by Wells Fargo & Company from $116.00 to $128.00. They now have an “equal weight” rating on the stock.
• 9/28/2026 – Incyte had its “buy” rating reaffirmed by UBS Group.
• 9/28/2026 – Incyte had its price target raised by JPMorgan Chase & Co. from $120.00 to $123.00. They now have a “neutral” rating on the stock.
• 9/28/2026 – Incyte had its price target raised by HC Wainwright from $150.00 to $152.00. They now have a “buy” rating on the stock.
• 9/22/2026 – Incyte had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $109.00 price target on the stock.

Incyte Price Performance

Shares of INCY opened at $122.27 on Thursday. Incyte Corporation has a 12 month low of $89.25 and a 12 month high of $132.60. The stock’s 50-day moving average is $119.46 and its two-hundred day moving average is $108.77. The stock has a market cap of $24.92 billion, a PE ratio of 65.04, a P/E/G ratio of 4.38 and a beta of 0.78.

Incyte (NASDAQ:INCY) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.93) by $0.33. The business had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The company’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.26 earnings per share. On average, research analysts anticipate that Incyte Corporation will post 2.24 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Thomas Tray sold 610 shares of the business’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $118.96, for a total transaction of $72,565.60. Following the transaction, the insider directly owned 21,126 shares of the company’s stock, valued at approximately $2,513,148.96. The trade was a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Steven H. Stein sold 240,193 shares of the company’s stock in a transaction on Friday, November 6th. The shares were sold at an average price of $118.39, for a total transaction of $28,436,449.27. Following the completion of the transaction, the chief marketing officer owned 30,916 shares of the company’s stock, valued at $3,660,145.24. This trade represents a 88.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 254,246 shares of company stock worth $30,162,968 in the last 90 days. 16.20% of the stock is owned by company insiders.

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.